Fluctuation of HER2 expression in breast: Carcinomas during the menstrual cycle

American Journal of Pathology

Volumn 155, Issue 5, 1999, Pages 1543-1547

  Balsari, Andrea ^a,b   Casalini, Patrizia ^a   Tagliabue, Elda ^a   Greco, Marco ^a   Pilotti, Silvana ^a   Agresti, Roberto ^a   Giovanazzi, Riccardo ^a   Alasio, Loredana ^a   Rumio, Cristiano ^a   Cascinelli, Natale ^a   Colnaghi, Maria Ines ^a   Ménard, Sylvie ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 0032753822     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65470-3     Document Type: Article

References (18)

1. Veronesi U, Luini A, Mariani L: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994, 343:1544-1546
2. Hagen AA, Hrushesky WJ: Menstrual timing of breast cancer surgery. Am J Surg 1998, 175:245-261
3. Hrushesky WJ: Menstrual cycle timing of breast cancer resection. Recent Results Cancer Res 1996, 140:27-40
4. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates, Cavalli F, Simoncini E, Fey MF; Pagani O, Price K, Senn HJ: Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 1997, 8:751-756
5. Badwe RA, Bettelheim R, Millis RR, Gregory W, Richards MA, Fentiman IS: Cyclical tumour variations in premenopausal women with early breast cancer. Eur J Cancer 1995, 31A:2181-2184
6. Rodgers WH, Matrisian LM, Giudice LC, Dsupin B, Cannon P, Svitek C, Gorstein F, Osteen KG: Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994, 94:946-953
7. Ferguson JE, Schor AM, Howell A, Ferguson MW, Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC: Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell Tissue Res 1992, 268:167-177
8. Saad Z, Bramwell VH, Wilson SM, O'Malley FP, Jeacock J, Chambers AF: Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998, 351:1170-1173
9. Ménard S, Casalini P, Agresti R, Pilotti S, Balsari A: Proliferation of breast carcinoma during menstrual phases. Lancet 1998, 352:148-149
10. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168: 357-363
11. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991
12. Landers JP, Spelsberg TC: New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr 1992, 2:19-63
13. Stancel GM, Baker VV, Hyder SM, Kirkland JL, Loose-Mitchell DS: Oncogenes and uterine function. Oxf Rev Reprod Biol 1993, 15:1-42
14. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990, 5:1001-1006
15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712
16. Oliver DJ, Ingram DM: Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 1995, 31A:325-328
17. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744
18. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58: 2825-2831